<DOC>
	<DOCNO>NCT00643513</DOCNO>
	<brief_summary>To study QoL related response , symptom spectrum severity disseminate breast cancer patient receive Faslodex hormonal therapy .</brief_summary>
	<brief_title>Quality Of Life While Receiving Faslodex</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Histologic and/or cytological proven breast cancer . Patients metastases breast cancer ± postmenopausal primary tumor ≥12 month . Positive oestrogen receptor ( ER+ ) , positive progesterone receptor ( PgR+ ) unknown hormonal receptor ( duration surgery metastasis occur less 2 year ) indirect confirmation hormone sensitive tumor . ECOG performance status ≤ 2 Patient willingness take part programm Life expectancy 6 month . Patient ability complete questionnaire . Contraindications Faslodex therapy Other anticancer therapy ( chemotherapy , hormonal therapy drug , radiotherapy ) , except radiotherapy site measurable evaluable manifestation disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>QUALITY OF LIFE</keyword>
	<keyword>POSTMENOPAUSAL WOMEN</keyword>
	<keyword>HORMONE RECEPTOR POSITIVE DISSEMINATED BREAST CANCER</keyword>
	<keyword>FASLODEX</keyword>
</DOC>